Literature DB >> 31431381

Differences between planned and delivered dose for head and neck cancer, and their consequences for normal tissue complication probability and treatment adaptation.

Jolien Heukelom1, Michael E Kantor2, Abdallah S R Mohamed3, Hesham Elhalawani3, Esengul Kocak-Uzel4, Timothy Lin3, Jinzhong Yang2, Michalis Aristophanous5, Coen R Rasch6, Clifton David Fuller3, Jan-Jakob Sonke7.   

Abstract

BACKGROUND AND
PURPOSE: Anatomical changes induce differences between planned and delivered dose. Adaptive radiotherapy (ART) may reduce these differences but the optimal implementation is insufficiently clear. The aims of this study were to quantify the difference between planned and delivered dose in HNC patients, assess the consequential difference in normal tissue complication probability (ΔNTCP) and to explore the value of ΔNTCP as an objective selection strategy for ART.
MATERIALS AND METHODS: For 52 patients, daily doses were accumulated to estimate the delivered dose. The difference from planned dose was analyzed for CTVs and 9 organs-at-risk (OAR). ΔNTCP was calculated for xerostomia, dysphagia, parotid gland dysfunction and tube feeding dependency at 6 months. ART was deemed necessary if ΔNTCP was >5%. The positive predicted value (PPV) was calculated for identification of ART-patients by clinical judgement, and ΔNTCP at fraction 10 and 15.
RESULTS: ΔNTCP >5% was seen five times for dysphagia and twice for the other toxicities. Only 5/9 patients with any ΔNTCP >5% clinically received ART, although ART had been done for 13/52 patients (PPV: 0.38). PPV was 0.86 and 0.75 for accumulated dose at fraction 10 and 15, respectively, using a ΔNTCP cut-off for the allocation of ART of 5%. Using other ΔNTCP cut-offs did not substantially improve PPV. With this cut-off the negative predictive value was 0.93 for ΔNTCP method of fraction 10 and fraction 15, and 0.90 for clinical judgement.
CONCLUSION: To identify patients accurately for ART, NTCP calculations based on the dose differences between planned and delivered dose at fraction 10 are superior to clinical judgement.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  ART; Dose-summation; Head and neck cancer; NTCP; Radiotherapy

Mesh:

Year:  2019        PMID: 31431381      PMCID: PMC7401328          DOI: 10.1016/j.radonc.2019.07.034

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  25 in total

1.  Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach.

Authors:  Johannes A Langendijk; Philippe Lambin; Dirk De Ruysscher; Joachim Widder; Mike Bos; Marcel Verheij
Journal:  Radiother Oncol       Date:  2013-06-05       Impact factor: 6.280

2.  Optimal adaptive IMRT strategy to spare the parotid glands in oropharyngeal cancer.

Authors:  Pengcheng Zhang; Antoine Simon; Bastien Rigaud; Joël Castelli; Juan David Ospina Arango; Mohamed Nassef; Olivier Henry; Jian Zhu; Pascal Haigron; Baosheng Li; Huazhong Shu; Renaud De Crevoisier
Journal:  Radiother Oncol       Date:  2016-06-29       Impact factor: 6.280

3.  Technical Note: The impact of deformable image registration methods on dose warping.

Authors:  An Qin; Jian Liang; Xiao Han; Nicolette O'Connell; Di Yan
Journal:  Med Phys       Date:  2018-01-20       Impact factor: 4.071

4.  Prospective Qualitative and Quantitative Analysis of Real-Time Peer Review Quality Assurance Rounds Incorporating Direct Physical Examination for Head and Neck Cancer Radiation Therapy.

Authors:  Carlos E Cardenas; Abdallah S R Mohamed; Randa Tao; Andrew J R Wong; Mussadiq J Awan; Shirly Kuruvila; Michalis Aristophanous; G Brandon Gunn; Jack Phan; Beth M Beadle; Steven J Frank; Adam S Garden; William H Morrison; Clifton D Fuller; David I Rosenthal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-19       Impact factor: 7.038

5.  The residual setup errors of different IGRT alignment procedures for head and neck IMRT and the resulting dosimetric impact.

Authors:  Pierre Graff; Neil Kirby; Vivian Weinberg; Josephine Chen; Sue S Yom; Louise Lambert; Jean Pouliot
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-12-11       Impact factor: 7.038

6.  Parotid gland function after radiotherapy: the combined michigan and utrecht experience.

Authors:  Tim Dijkema; Cornelis P J Raaijmakers; Randall K Ten Haken; Judith M Roesink; Pètra M Braam; Anette C Houweling; Marinus A Moerland; Avraham Eisbruch; Chris H J Terhaard
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-07       Impact factor: 7.038

7.  Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system.

Authors:  Jerry L Barker; Adam S Garden; K Kian Ang; Jennifer C O'Daniel; He Wang; Laurence E Court; William H Morrison; David I Rosenthal; K S Clifford Chao; Susan L Tucker; Radhe Mohan; Lei Dong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-15       Impact factor: 7.038

8.  Parotid gland dose in intensity-modulated radiotherapy for head and neck cancer: is what you plan what you get?

Authors:  Jennifer C O'Daniel; Adam S Garden; David L Schwartz; He Wang; Kian K Ang; Anesa Ahamad; David I Rosenthal; William H Morrison; Joshua A Asper; Lifei Zhang; Shih-Ming Tung; Radhe Mohan; Lei Dong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-15       Impact factor: 7.038

9.  Radiation-induced volume changes in parotid and submandibular glands in patients with head and neck cancer receiving postoperative radiotherapy: a longitudinal study.

Authors:  Zhong-He Wang; Chao Yan; Zhi-Yuan Zhang; Chen-Ping Zhang; Hai-Sheng Hu; Jessica Kirwan; William M Mendenhall
Journal:  Laryngoscope       Date:  2009-10       Impact factor: 3.325

10.  Adaptive radiotherapy for head and neck cancer--dosimetric results from a prospective clinical trial.

Authors:  David L Schwartz; Adam S Garden; Shalin J Shah; Gregory Chronowski; Samir Sejpal; David I Rosenthal; Yipei Chen; Yongbin Zhang; Lifei Zhang; Pei-Fong Wong; John A Garcia; K Kian Ang; Lei Dong
Journal:  Radiother Oncol       Date:  2013-01-29       Impact factor: 6.280

View more
  4 in total

1.  Initial Feasibility and Clinical Implementation of Daily MR-Guided Adaptive Head and Neck Cancer Radiation Therapy on a 1.5T MR-Linac System: Prospective R-IDEAL 2a/2b Systematic Clinical Evaluation of Technical Innovation.

Authors:  Brigid A McDonald; Sastry Vedam; Jinzhong Yang; Jihong Wang; Pamela Castillo; Belinda Lee; Angela Sobremonte; Sara Ahmed; Yao Ding; Abdallah S R Mohamed; Peter Balter; Neil Hughes; Daniela Thorwarth; Marcel Nachbar; Marielle E P Philippens; Chris H J Terhaard; Daniel Zips; Simon Böke; Musaddiq J Awan; John Christodouleas; Clifton D Fuller
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-12-16       Impact factor: 7.038

2.  Accurate estimation of daily delivered radiotherapy dose with an external treatment planning system.

Authors:  Takahiro Kanehira; Stina Svensson; Simon van Kranen; Jan-Jakob Sonke
Journal:  Phys Imaging Radiat Oncol       Date:  2020-05-29

3.  Future-proof Radiation therapist (RTT) practice in a pandemic - Lessons learnt from COVID-19.

Authors:  Maeve Kearney; Mary Coffey; Maddalena Rossi; Yat Tsang
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2021-02-05

4.  Early Prediction of Planning Adaptation Requirement Indication Due to Volumetric Alterations in Head and Neck Cancer Radiotherapy: A Machine Learning Approach.

Authors:  Vasiliki Iliadou; Ioannis Kakkos; Pantelis Karaiskos; Vassilis Kouloulias; Kalliopi Platoni; Anna Zygogianni; George K Matsopoulos
Journal:  Cancers (Basel)       Date:  2022-07-22       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.